A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK

BACKGROUND: International guidelines recommend nintedanib (OFEV(®)) as an option for the treatment of idiopathic pulmonary fibrosis (IPF). OBJECTIVE: The objective of this study was to assess the cost effectiveness of nintedanib versus pirfenidone, N-acetylcysteine and best supportive care (BSC) for...

Descripción completa

Detalles Bibliográficos
Autores principales: Rinciog, C., Watkins, M., Chang, S., Maher, T. M., LeReun, C., Esser, D., Diamantopoulos, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357477/
https://www.ncbi.nlm.nih.gov/pubmed/28039616
http://dx.doi.org/10.1007/s40273-016-0480-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357477/
https://www.ncbi.nlm.nih.gov/pubmed/28039616
http://dx.doi.org/10.1007/s40273-016-0480-2

Ejemplares similares